NervGen Pharma Corp
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more
NervGen Pharma Corp (NGENF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 1.808x
Based on the latest financial reports, NervGen Pharma Corp (NGENF) has a cash flow conversion efficiency ratio of 1.808x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.32 Million) by net assets ($-2.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NervGen Pharma Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NervGen Pharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NervGen Pharma Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NervGen Pharma Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UNISEM Co. Ltd
KQ:036200
|
0.022x |
|
Richardson Electronics Ltd
NASDAQ:RELL
|
-0.001x |
|
Zhejiang Meishuo Electric Technology Co. Ltd. A
SHE:301295
|
N/A |
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
0.046x |
|
OrganiGram Holdings Inc
NASDAQ:OGI
|
-0.043x |
|
Open Orphan plc
PINK:OPORF
|
-0.173x |
|
Vinte Viviendas Integrales S.A.B. de C.V
MX:VINTE
|
-0.033x |
|
Global Standard Technology Limited
KQ:083450
|
0.015x |
Annual Cash Flow Conversion Efficiency for NervGen Pharma Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of NervGen Pharma Corp from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.58 Million | $-16.84 Million | -6.536x | -216.26% |
| 2023-12-31 | $-2.01 Million | $-11.30 Million | 5.622x | +525.55% |
| 2022-12-31 | $13.46 Million | $-17.78 Million | -1.321x | -168.70% |
| 2021-12-31 | $16.82 Million | $-8.27 Million | -0.492x | +53.78% |
| 2020-12-31 | $5.92 Million | $-6.30 Million | -1.064x | +23.23% |
| 2019-12-31 | $5.84 Million | $-8.09 Million | -1.386x | -234.95% |
| 2018-12-31 | $2.51 Million | $-1.04 Million | -0.414x | -100.47% |
| 2017-12-31 | $-11.81K | $-1.04 Million | 88.045x | -- |